rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease (CAN-GT)

• ClinicalTrials.gov Identifier: NCT04833907
• Recruitment Status: Recruiting
• First Posted: April 6, 2021
• Last Update Posted: April 11, 2024
• Sponsor: Myrtelle Inc.
• Information provided by (Responsible Party): Myrtelle Inc.

Tracking Information

• First Submitted Date: March 24, 2021
• First Posted Date: April 6, 2021
• Last Update Posted Date: April 11, 2024
• Actual Study Start Date: April 1, 2021
• Estimated Primary Completion Date: August 31, 2026 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: June 8, 2022)

Safety evaluation [ Time Frame: 12 Months Post Dose ]

Number, severity, and causal relationship of any adverse event (to either the gene therapy and/or surgical trial procedures required for vector administration) using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

Original Primary Outcome Measures (submitted: April 2, 2021)

Safety evaluation [ Time Frame: up to 2 years ]

Number, severity, and causal relationship of any adverse event (to either the gene therapy and/or surgical trial procedures required for vector administration) using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

Current Secondary Outcome Measures (submitted: June 8, 2022)

• Myelination [ Time Frame: 12 Months Post Dose ]
  Change from baseline measured by cerebral Synthetic Magnetic Resonance Imaging (SyMRI)
• N-Acetyl-Aspartate (NAA) concentrations in the Brain [ Time Frame: 12 Months Post Dose ]
  N-Acetyl-Aspartate concentrations will be assessed with nuclear Magnetic Resonance Spectroscopy (nMRS) between pre- and post-treatment and as compared to historical controls.
• Neurological Evaluation - Motor Function [ Time Frame: 12 Months Post Dose ]
  Motor Function will be analyzed using the Gross Motor Function Measure (GMFM)-88 scale for motor function assessment before and after vector administration and compared to historical controls. The GMFM consists of 5 scales: Lying and Rolling, Sitting, Crawling and Kneeling, Standing and Walking, Running and Jumping. The total scores range from 0 to 264. The lower the score on GMFM, the weaker the ability; the higher the score, the greater the ability.
• Neurological Evaluation - Neurocognitive Function [ Time Frame: 12 Months Post Dose ]
  Neurocognitive function will be assessed using the Mullen Scales of Early Learning (MSEL) before and after vector administration and compared to historical controls. The MSEL is a cognitive test to measure cognitive ability and language development. The MSEL test has five scales: Gross motor, Visual reception, Fine motor, Receptive language, and Expressive language. The total scores range from 0 to 197. The lower the score on MSEL, the weaker the ability; the higher the score, the greater the ability.
• Neurological Evaluation - Spasticity [ Time Frame: 12 Months Post Dose ]
  Will be assessed using the Canavan Neurological Evaluation before and after vector administration and compared to historical controls.
• Seizure Assessment [ Time Frame: 12 Months Post Dose ]
  Will be assessed based on reported seizure activity and Electroencephalograms alpha, beta, delta, and theta wave frequencies (Hz).
• NAA concentration measured in Cerebrospinal Fluid (CSF) [ Time Frame: 6 months ]
  CSF will be collected via lumbar puncture and analyzed to assess concentrations of N-Acetyl-Aspartate.

Original Secondary Outcome Measures (submitted: April 2, 2021)

• Myelination [ Time Frame: up to 2 years ]
  Change from baseline in fractional anisotropy (FA) post vector administration will be measured by cerebral Magnetic Resonance Imaging and special Diffusion Tensor Imaging sequences.
• Brain Atrophy [ Time Frame: up to 2 years ]
  Rate of whole brain atrophy (T2 - T0): Percentage brain volume change (PBVC) will be estimated from the 3D T-1 weighted acquisition
• N-Acetyl-Aspartate (NAA) concentrations in the Brain [ Time Frame: up to 2 years ]
  N-Acetyl-Aspartate concentrations will be assessed with nuclear Magnetic Resonance Spectroscopy (nMRS) between pre- and post-treatment and as compared to historical controls.
• Neurological Evaluation - Motor Function [ Time Frame: up to 2 years ]
  Will be analyzed using the Gross Motor Function Measure (GMFM)-88 scale for motor function assessment before and after vector administration and as compared to historical controls.
• Neurological Evaluation - Neurocognitive Function [ Time Frame: up to 2 years ]
  Will be assessed using the Mullen Scales of Early Learning for cognitive and motor function assessment before and after vector administration and as compared to historical controls.
• Neurological Evaluation - Spasticity [ Time Frame: up to 2 years ]
  Will be assessed using the Canavan Neurological Evaluation before and after vector administration and as compared to historical controls.
• Seizure Assessment [ Time Frame: up to 2 years ]
  Will be assessed using a Seizure Diary and Electroencephalograms alpha, beta, delta, and theta wave frequencies (Hz).
• Cerebrospinal Fluid Analysis (CSF) [ Time Frame: 12 months ]
  CSF will be collected via lumbar puncture and analyzed to assess concentrations of N-Acetyl-Aspartate.

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease
• Official Title: Phase 1/2, Open Label, Sequential Cohort Study of a Single Intracranial Dose of AVASPA Gene Therapy for Treatment of Children With Typical Canavan Disease

Brief Summary

Canavan Disease is a congenital white matter disorder caused by mutations to the gene encoding for aspartoacylase (ASPA). Expression of ASPA is restricted to oligodendrocytes, the sole white matter producing lineage in the brain. ASPA supports myelination in the capacity of its sole known function, namely, the catabolism of N-acetylaspartate (NAA). Inherited mutations that result in loss of ASPA catabolic activity result in a typically severe phenotype of Canavan Disease, characterized by chronically elevated brain NAA, gross motor abnormalities, hypomyelination, progressive spongiform degeneration of the brain, epilepsy, blindness, and a short life expectancy. Disease severity is correlated with residual levels of enzyme activity. Reconstitution of ASPA function in oligodendrocytes of the brains of Canavan patients is expected to rescue NAA metabolism in its natural cellular compartment and support myelination/remyelination by resident white matter producing cells. This protocol directly targets oligodendrocytes in the brain, which are intimately involved with disease initiation and progression. Targeting oligodendrocytes offers the safest and most direct therapy for affected individuals.

The latest generation AAV viral vector (rAAV-Olig001-ASPA) will be administered to patients using neurosurgical procedure which involves direct administration of gene therapy to affected regions of the brain. Outcome measures for the open label clinical trial include longitudinal clinical assessments and brain imaging.

Currently, there is no effective treatment for Canavan Disease. The purpose of this study is to validate a new technology targeted to the cells most affected by Canavan Disease in the safest way possible.

The study investigators are committed to supporting the Rare Disease & Canavan Disease Communities. For more information, please contact Jordana Holovach, Head of Communications and Community at PatientAdvocacy@myrtellegtx.com.

Detailed Description

rAAV-Olig001-ASPA is the first gene therapy designed to target the oligodendrocytes, which are critical for myelination and brain development.

This study is a Phase 1/2 First-In-Human protocol designed to obtain safety, pharmacodynamics, and efficacy data following neurosurgical administration of a single dose of rAAV-Olig001-ASPA delivered intracerebroventricularly in up to 24 children with Canavan Disease.

Patients with a diagnosis of typical Canavan Disease who meet all eligibility criteria may be enrolled in this open-label, sequential cohort study of a single dose of rAAV-Olig001-ASPA.

• Study Type: Interventional
• Study Phase: Phase 1; Phase 2
• Study Design: Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Canavan Disease

Intervention

• Drug: rAAV-Olig001-ASPA
  Intracerebroventricular administration of a single dose
  Other Name: MYR-101
• Drug: Levetiracetam
  Keppra daily dose (20-50 mg/kg/day divided twice daily administered orally or per G-tube) in the post-operative period and continued for 3 months per standard of care to prevent seizure activity.
  Other Name: Keppra
• Drug: Prednisone
  Post-operatively, a 3-month steroid taper is planned to prevent or reduce possible delayed immunological responses. This tapering regimen will consist of 0.5 mg/kg/day prednisone during weeks 1-4; followed by 0.3 mg/kg/day prednisone during weeks 5-8; and 0.1mg prednisone during weeks 9-12, then off. If there is evidence of new inflammation on MRI at 3-months on T2 FLAIR, the steroid taper will be extended for an additional 3 months or we will transition to steroid-sparing immunosuppression.

Study Arms

Experimental: 3.7 x 10^13 v.g. rAAV-Olig001-ASPA

3.7 x 10^13 v.g. of rAAV-Olig001-ASPA administered as a single dose neurosurgically to the brain via 2 pre-defined intracerebroventricular sites

Interventions:

• Drug: rAAV-Olig001-ASPA
• Drug: Levetiracetam
• Drug: Prednisone

Publications *

• Francis JS, Markov V, Wojtas ID, Gray S, McCown T, Samulski RJ, Figueroa M, Leone P. Preclinical biodistribution, tropism, and efficacy of oligotropic AAV/Olig001 in a mouse model of congenital white matter disease. Mol Ther Methods Clin Dev. 2021 Jan 21;20:520-534. doi: 10.1016/j.omtm.2021.01.009. eCollection 2021 Mar 12.
• Francis JS, Wojtas I, Markov V, Gray SJ, McCown TJ, Samulski RJ, Bilaniuk LT, Wang DJ, De Vivo DC, Janson CG, Leone P. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase. Neurobiol Dis. 2016 Dec;96:323-334. doi: 10.1016/j.nbd.2016.10.001. Epub 2016 Oct 4.

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: April 2, 2021): 24
• Original Estimated Enrollment: Same as current
• Estimated Study Completion Date: August 31, 2027
• Estimated Primary Completion Date: August 31, 2026 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Definitive diagnosis of typical CD by a board certified neurologist.
• Written informed consent from parent(s)/guardian(s). Consent to enroll into the study will include a written agreement to comply with all the conditions of the study, including attendance at follow-up visits.
• For cohort 1: age more than 36 months and up to 60 months.
• For cohort 2: age between 15 months and 36 months.
• For cohort 3: age less than 15 months.

Exclusion Criteria:

• At the discretion of the PI, any significant chronic medical condition, including, but not limited to neurological, cardiac, hepatic, renal, hematological, gastrointestinal, endocrine, pulmonary, or infectious disease, which would put the subject at increased risk during surgery or which would interfere with participation in the study, interpretation of safety monitoring, or the integrity of the study data.
• History of severe allergic reaction or anaphylaxis.
• Past participation in gene therapy trials or receipt of any other investigational product within 6 months prior to enrollment.
• Prior intracranial surgery.
• Any absolute contraindication to immunosuppression.
• Any absolute contraindication to MRI.
• Any vaccination less than 1 month prior to gene therapy.
• Anticipated life expectancy of less than 12 months for any reason.
• GMFM-88 total raw score >35%.
• Clinically significant out-of-range lab values, at the discretion of clinical PI.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 3 Months to 60 Months (Child)
• Accepts Healthy Volunteers: No

Contacts

Contact: Jordana Holovach; patientadvocacy@myrtellegtx.com

Contact: Olga Flamini, MD, PhD; oflamini@myrtellegtx.com

• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT04833907
• Other Study ID Numbers: CAN-GT
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: Myrtelle Inc.
• Original Responsible Party: CureRareDisease LLC
• Current Study Sponsor: Myrtelle Inc.
• Original Study Sponsor: CureRareDisease LLC
• Collaborators: Not Provided

Investigators

• Principal Investigator: Christopher G Janson, MD; Dayton Children's Hospital
• Principal Investigator: Robert Lober, MD, PhD; Dayton Children's Hospital

• PRS Account: Myrtelle Inc.
• Verification Date: December 2023